ceDNA Vectors for Gaucher Disease Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods using adeno-associated virus (AAV) vectors are limited by their small viral packaging capacity, immune response issues, and slow gene expression, which restricts their effectiveness in treating diseases like Gaucher disease, particularly in achieving sustained and repeatable delivery of therapeutic proteins.
Innovation Solution
The use of capsid-free, non-viral DNA vectors with covalently-closed ends (ceDNA vectors) encoding the GBA protein, which can be formulated in liposome nanoparticle form for efficient and repeatable delivery, allowing for rapid onset and sustained expression of therapeutic levels in cells such as those in the liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AAV vectors are used for gene delivery, then transduction efficiency and persistence are improved, but packaging capacity is limited to about 4.5 kb
Solution Approach 1:
The patent segments the gene delivery system into two parts: (1) a large-capacity non-viral DNA vector that carries the therapeutic gene cargo, and (2) a separate protein transduction domain (PTD) that enables cellular uptake. This segmentation allows the DNA vector to accommodate large gene sequences (exceeding 4.5 kb) without being constrained by AAV packaging limits, while the PTD component provides the transduction functionality that would otherwise require viral vectors.
Solution Approach 2:
The patent introduces a protein transduction domain (PTD) as an intermediary component that mediates cellular uptake of the non-viral DNA vector. The PTD acts as a bridge between the DNA cargo and the cell membrane, enabling efficient transduction without requiring viral capsids. This intermediary approach allows the system to achieve transduction efficiency comparable to viral vectors while maintaining the large packaging capacity of non-viral vectors.
2Duration of action of stationary object
If AAV vectors are used for gene delivery, then sustained expression is achieved, but immune response and neutralizing antibodies are triggered
Solution Approach 1:
The patent extracts the immunogenic components (viral capsids and associated proteins) from the gene delivery system while retaining the essential functions of transduction and sustained expression. By using a non-viral DNA vector combined with a synthetic PTD, the system eliminates the immune response triggered by viral components, yet maintains the ability to achieve sustained therapeutic expression through the stable integration and long-term activity of the DNA vector.
Solution Approach 2:
The patent employs a disposable non-viral DNA vector system that does not require the complex, immunogenic viral capsid structures. The DNA vector is designed to be transient yet sufficiently persistent for therapeutic effect, avoiding the long-term immune responses associated with viral vectors. This approach uses simpler, less immunogenic materials that can be safely administered without triggering neutralizing antibodies.
3Length of moving object
If non-viral DNA vectors are used, then packaging capacity and repeatable delivery are improved, but transduction efficiency and cellular uptake are reduced
Solution Approach 1:
The patent creates a composite gene delivery system by combining a non-viral DNA vector (providing large packaging capacity) with a protein transduction domain (PTD) (providing efficient cellular uptake). The PTD component, when fused to or associated with the DNA vector, dramatically enhances transduction efficiency and cellular internalization, compensating for the inherently lower efficiency of non-viral vectors. This composite approach allows the system to simultaneously achieve large cargo capacity and high transduction efficiency.
4Reliability
If AAV vectors are used, then gene expression is achieved, but onset of expression is slow
Solution Approach 1:
The patent employs a preliminary action strategy by using a non-viral DNA vector that can be rapidly delivered and expressed without the slow conversion process required by AAV. The DNA vector is designed for immediate cellular uptake and rapid transcriptional activity, providing fast onset of therapeutic expression. The vector includes optimized promoter elements and structural features that enable quick gene expression activation, eliminating the delayed onset characteristic of AAV-mediated expression.
Data Source
AI summary
The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding GBA protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of GBA protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of GBA protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing GBA protein. Such GBA protein can be expressed for treating disease, e.g., Gaucher disease.